Compare Stryker Corporation (SYK) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Stryker Corporation vs Twist Bioscience Corp — how do they compare? Stryker Corporation trades at $277.44 (market cap $105.63B), while Twist Bioscience Corp trades at $125.52 (market cap $8.26B). The key difference: Stryker Corporation is far larger — about 12.8× Twist Bioscience Corp's market cap, and Stryker Corporation pays a 1.28% dividend while Twist Bioscience Corp pays none. Which is the better fit depends on your goals.
| SYK | TWST | |
|---|---|---|
Market Cap | $105.63B | $8.26B |
Sector | Technology | Health |
52-Week High | $388.79 | $153.10 |
52-Week Low | $275.39 | $24.16 |
Enterprise Value | $117.10B | $8.18B |
Dividend Yield | 1.28% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Stryker Corporation (SYK) trades at $276.43, down 8.81% over 24 hours, reflecting bearish technical signals but strong fundamentals. The stock shows robust profitability with a 14.43% net income margin and consistent earnings beats in recent quarters. Recent developments include the launch of an FDA-cleared surgical app for Apple Vision Pro and the acquisition of ZuriMED to expand shoulder care offerings. Analyst consensus remains strongly bullish with a $372.89 price target, though ongoing securities fraud investigations pose near-term sentiment risks.
Outlook is positive long-term due to solid financial health, innovation pipeline, and institutional support, but investors face volatility from legal probes and technical bearishness. The stock's current dip may present a buying opportunity for those confident in Stryker's market position and growth trajectory, balanced against regulatory and market risks.
Twist Bioscience (TWST) trades at $128.06, up 2.68% with a bearish technical signal despite recent AI-driven momentum. The company shows strong revenue growth (2025: $377M, 2026: $432M projected) but continues to report significant losses with negative net margins. Recent news highlights AI partnerships and a $300M stock offering, while analyst consensus remains predominantly bullish with 78.6% buy ratings.
TWST presents a high-risk growth opportunity with accelerating revenue but persistent profitability challenges. The stock's valuation appears stretched at P/S of 18.09, requiring successful execution on AI initiatives and path to EBITDA breakeven. Key risks include cash burn, competitive pressures, and dependence on emerging AI-driven drug discovery markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Stryker Corporation
Stryker is a global leader in medical technology, specializing in Orthopaedics, MedSurg, and Neurotechnology. It is renowned for its highly decentralized business model, which empowers 22 specialized business units to drive innovation and category leadership. With its market-leading Mako SmartRobotics™ platform and a relentless M&A strategy, Stryker provides a comprehensive ecosystem of connected surgical tools, implants, and digital solutions that improve both clinical and financial outcomes for hospitals worldwide.
Read more on SYK →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
